Ertugliflozin for Functional Mitral Regurgitation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.
Also called NCT04231331
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 128 participants
- Registry
-
NCT04231331
-
- Other papers using this trial's data
- Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04231331. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-04 (actual); primary completion 2023-11-15 (actual). Results posted on 2025-01-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ertugliflozin for Functional Mitral Regurgitation
- Acronym
- EFFORT
- Condition
- Mitral Valve Insufficiency
- Condition
- Left Ventricular Systolic Dysfunction
- Intervention (Drug)
- Ertugliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Asan Medical Center
- Collaborator
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct04231331- Content hash
de009f5cdeefb5e4f3343400be1e3eeb8952ce1c2477ff9895087bc638116b94